Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL) Meeting Abstract
| Authors: | Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; Yahalom, J.; Rademaker, J.; Dogan, A.; Seshan, V.; Younes, A. |
| Abstract Title: | Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL) |
| Meeting Title: | 15th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 37 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 Jun 18-22 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2019-06-01 |
| Start Page: | 331 |
| End Page: | 332 |
| Language: | English |
| ACCESSION: | 137029154 |
| DOI: | 10.1002/hon.143_2630 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| PUBMED: | 31187525 |
| DOI/URL: | |
| Notes: | Meeting abstract: 279 -- Accession Number: 137029154 -- Entry Date: In Process -- Revision Date: 20190620 -- Publication Type: Article -- Supplement Title: Jun2019 Supplement S2 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
